Related Experiment Video
Updated: Aug 23, 2026

A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems
Published on: December 24, 2014
Mechanistic PBPK/PD modeling of PFOS-associated cholesterol response and its application in human health risk
Go-Wun Choi1, Dong Wook Kang1, Ju Hee Kim1
1College of Pharmacy, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.
Abstract:
The present study aims to develop a PBPK/PD model of PFOS in rats and its extrapolation to humans for risk assessment. Age effect was explored in rats as a potential covariate impact on the pharmacokinetics of PFOS. Peri-adolescent rats showed lower exposure to PFOS compared to adult rats, suggesting immature reabsorption. Therefore, ontogenic development process was applied to the PBPK model for body weight, transport maximum (Tm), and distribution parameters in rats. Cholesterol level was selected as a pharmacodynamic (PD) biomarker with an indirect PD response model. The human PBPK model was developed through extrapolation from rats by applying allometric scaling. Furthermore, literature epidemiology data were used to build a PD response model in humans, with an association-based PD response model linking PFOS exposure to cholesterol production rate. The developed PBPK/PD model in humans was applied to risk assessment for forward and reverse dosimetry to set the threshold estimate of daily intake (EDI) and to investigate the current health risk of PFOS using Korean biomonitoring data, respectively. The threshold EDI was calculated for a target of 5% cholesterol increase using a Markov chain Monte Carlo simulation with a value of 3.48 ng/kg/day for the adult population. The estimated EDI was 1.02 ng/kg/day by reverse dosimetry in adults. The predicted increase in cholesterol was below 5% of the population median in every age group, although the 95th percentile in the geriatric group reached 6.9%. In conclusion, the present study provides a mechanistic framework for integrating ontogenic development and PD response with the PBPK model for risk assessment.
Related Concept Videos
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Mechanistic Models: Compartment Models in Individual and Population Analysis
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Microbial Bioremediation of Pesticides
